Race Oncology logo

RAC - Race Oncology Share Price

A$0.775 0.0  0.0%

Last Trade - 08/07/20

Sector
Healthcare
Size
Micro Cap
Market Cap £46.7m
Enterprise Value £45.9m
Revenue £4.82k
Position in Universe 730th / 1839
Bullish
Bearish
Unlock RAC Revenue
Momentum
Relative Strength (%)
1m +147.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.003 0.000 0.017 0.025 0.022 0.017 +43.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2019, Race Oncology Ltd revenues decreased 75% to A$3K. Net loss decreased 26% to A$1.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Business development and marketing decrease of 89% to A$37K (expense), R&D manufacturing and distribution decrease of 70% to A$114K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RAC Revenue Unlock RAC Revenue

Net Income

RAC Net Income Unlock RAC Revenue

Normalised EPS

RAC Normalised EPS Unlock RAC Revenue

PE Ratio Range

RAC PE Ratio Range Unlock RAC Revenue

Dividend Yield Range

RAC Dividend Yield Range Unlock RAC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RAC EPS Forecasts Unlock RAC Revenue
Profile Summary

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated February 15, 2011
Public Since July 13, 2016
No. of Shareholders: 868
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 109,144,901
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RAC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RAC
Upcoming Events for RAC
Friday 20th November, 2020 Estimate
Race Oncology Ltd Annual Shareholders Meeting
Frequently Asked Questions for Race Oncology
What is the Race Oncology share price?

As of 08/07/20, shares in Race Oncology are trading at A$0.775, giving the company a market capitalisation of £46.7m. This share price information is delayed by 15 minutes.

How has the Race Oncology share price performed this year?

Shares in Race Oncology are currently trading at A$0.775 and the price has moved by 1.51k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Race Oncology price has moved by 1.72k% over the past year.

What are the analyst and broker recommendations for Race Oncology?

Of the analysts with advisory recommendations for Race Oncology, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Race Oncology is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Race Oncology next release its financial results?

Race Oncology is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Race Oncology dividend yield?

Race Oncology does not currently pay a dividend.

Does Race Oncology pay a dividend?

Race Oncology does not currently pay a dividend.

When does Race Oncology next pay dividends?

Race Oncology does not currently pay a dividend.

How do I buy Race Oncology shares?

To buy shares in Race Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Race Oncology?

Shares in Race Oncology are currently trading at A$0.775, giving the company a market capitalisation of £46.7m.

Where are Race Oncology shares listed? Where are Race Oncology shares listed?

Here are the trading details for Race Oncology:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: RAC
What kind of share is Race Oncology?

Based on an overall assessment of its quality, value and momentum, Race Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Race Oncology share price forecast 2020?

We were not able to load any forecast data for Race Oncology.

How can I tell whether the Race Oncology share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Race Oncology. Over the past six months, the relative strength of its shares against the market has been 0.240k%. At the current price of A$0.775, shares in Race Oncology are trading at 0.193k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Race Oncology PE Ratio?

We were not able to find PE ratio data for Race Oncology.

Who are the key directors of Race Oncology?

Race Oncology's management team is headed by:

William Garner - NED
Chris Ntoumenopoulos - DRC
Peter Webse - SEC
John Cullity - CSO
Samar Al-Behaisi - VPR
Daniel Tillett - CHM
Borje Andersson - NED
Phillip Lynch - NED
Who are the major shareholders of Race Oncology?

Here are the top five shareholders of Race Oncology based on the size of their shareholding:

Garner (William James) Individual Investor
Percentage owned: 11.9% (13.9m shares)
Tillett (Daniel) Individual Investor
Percentage owned: 7.86% (9.20m shares)
Merchant Funds Management Pty Ltd Investment Advisor
Percentage owned: 7.29% (8.53m shares)
Molloy (Peter) Individual Investor
Percentage owned: 3.68% (4.31m shares)
Cullity (John) Individual Investor
Percentage owned: 3.24% (3.79m shares)
Similar to RAC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.